These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32641971)

  • 1. FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy.
    Zali H; Golchin A; Farahani M; Yazdani M; Ranjbar MM; Dabbagh A
    Iran J Pharm Res; 2019; 18(3):1639-1647. PubMed ID: 32641971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecules as Toll-like Receptor 4 Modulators Drug and
    Pérez-Regidor L; Guzmán-Caldentey J; Oberhauser N; Punzón C; Balogh B; Pedro JR; Falomir E; Nurisso A; Mátyus P; Menéndez JC; de Andrés B; Fresno M; Martín-Santamaría S
    Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening.
    Švajger U; Brus B; Turk S; Sova M; Hodnik V; Anderluh G; Gobec S
    Eur J Med Chem; 2013; 70():393-9. PubMed ID: 24177366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toll-like receptor 4: the potential therapeutic target for neuropathic pain].
    Jia ZJ; Wu FX; Huang QH; Liu JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Apr; 34(2):168-73. PubMed ID: 22776604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.
    Brindha S; Sundaramurthi JC; Velmurugan D; Vincent S; Gnanadoss JJ
    Bioinformation; 2016; 12(8):359-367. PubMed ID: 28275291
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mellini M; Di Muzio E; D'Angelo F; Baldelli V; Ferrillo S; Visca P; Leoni L; Polticelli F; Rampioni G
    Front Microbiol; 2019; 10():2355. PubMed ID: 31649658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in silico approach towards the identification of novel inhibitors of the TLR-4 signaling pathway.
    Mahita J; Harini K; Rao Pichika M; Sowdhamini R
    J Biomol Struct Dyn; 2016 Jun; 34(6):1345-62. PubMed ID: 26264972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of Notch1 and TLR4 signaling pathways in DRG neurons of in vivo and in vitro models of diabetic neuropathy.
    Chen T; Li H; Yin Y; Zhang Y; Liu Z; Liu H
    Sci Rep; 2017 Nov; 7(1):14923. PubMed ID: 29097792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of a New Class of Toll-Like Receptor 4 (TLR4) Tryptamine Related Agonists by Means of the Structure- and Ligand-Based Virtual Screening for Vaccine Adjuvant Discovery.
    Honegr J; Dolezal R; Malinak D; Benkova M; Soukup O; Almeida JSFD; Franca TCC; Kuca K; Prymula R
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29300367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation expression of toll-like receptor4 (TLR4) caused by the dysregulation of microRNA-140-5p is responsible for the development of postoperation infection.
    Zheng G; Li Z; Xiang W; Huang Y; Pan M
    J Cell Biochem; 2019 Mar; 120(3):3479-3490. PubMed ID: 30321456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.
    Shi Z; Yu T; Sun R; Wang S; Chen XQ; Cheng LJ; Liu R
    Pharmacogn Mag; 2016; 12(46):139-44. PubMed ID: 27076751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-Silico Identification of the Best Compound Against
    Saki J; Shadnoush F; Arjmand R; Rahim F
    Turkiye Parazitol Derg; 2019 Dec; 43(4):158-164. PubMed ID: 31865648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enrichment assessment of multiple virtual screening strategies for Toll-like receptor 8 agonists based on a maximal unbiased benchmarking data set.
    Pei F; Jin H; Zhou X; Xia J; Sun L; Liu Z; Zhang L
    Chem Biol Drug Des; 2015 Nov; 86(5):1226-41. PubMed ID: 26017460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of novel TLR4 ligands by in silico screening and their functional and structural characterization in vitro.
    Honegr J; Malinak D; Dolezal R; Soukup O; Benkova M; Hroch L; Benek O; Janockova J; Kuca K; Prymula R
    Eur J Med Chem; 2018 Feb; 146():38-46. PubMed ID: 29407964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists.
    Zhang X; Cui F; Chen H; Zhang T; Yang K; Wang Y; Jiang Z; Rice KC; Watkins LR; Hutchinson MR; Li Y; Peng Y; Wang X
    J Chem Inf Model; 2018 Apr; 58(4):816-825. PubMed ID: 29518316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation.
    Sohraby F; Bagheri M; Aryapour H
    Methods Mol Biol; 2019; 1903():23-43. PubMed ID: 30547434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study.
    Ai N; Wood RD; Welsh WJ
    Pharm Res; 2015 Aug; 32(8):2798-807. PubMed ID: 25762088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.